ACQUIRED PROLONGED QT INTERVAL AND TORSADES-DE-POINTES INDUCED BY ERYTHROMYCIN

被引:0
|
作者
STAIKOWSKY, F
GUIDET, B
BLANCHIN, I
BELAS, F
GABILLET, JM
机构
来源
SEMAINE DES HOPITAUX | 1991年 / 67卷 / 25期
关键词
ERYTHROMYCIN; ACQUIRED PROLONGED QT INTERVAL; TORSADES-DE-POINTES; VAUGHAN-WILLIAMS CLASS LA ANTIARRHYTHMIC AGENT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Erythromycin can induce prolongation of the QT interval on the ECG with a risk of << torsades de pointes >>. Fourteen such cases have been reported in the literature. In vitro and in vivo electrophysiologic studies have shown that this antibiotic has concentration-dependent effects on cardiac fibers similar to those of antiarrhythmic agents belonging to the Vaughan-Williams class Ia. However, this adverse effect is only very infrequently seen with this widely used drug and seems to occur in patients with other factors promoting prolongation of the QT interval.
引用
收藏
页码:1169 / 1171
页数:3
相关论文
共 50 条
  • [21] Pharmacological treatment of acquired QT prolongation and torsades de pointes
    Thomas, Simon H. L.
    Behr, Elijah R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (03) : 420 - 427
  • [22] TORSADES-DE-POINTES - ARRHYTHMIA, SYNDROME, OR CHIMERA
    MILLAR, RNS
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 (01) : 201 - 202
  • [23] Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review
    Khan, Fahadullah
    Ismail, Mohammad
    Khan, Qasim
    Ali, Zahid
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (10) : 1029 - 1039
  • [24] EXPERIMENTAL-MODELS OF TORSADES-DE-POINTES
    WEISSENBURGER, J
    DAVY, JM
    CHEZALVIEL, F
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1993, 7 (01) : 29 - 38
  • [25] Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
    Darpö, B
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2001, 3 (0K) : K70 - K80
  • [26] QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine
    Malone, Katie
    Hancox, Jules C.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2020, 11
  • [27] QT interval prolongation and the risk of torsades de pointes: essentials for clinicians
    Trinkley, Katy E.
    Page, Robert Lee, II
    Lien, Hoang
    Yamanouye, Kevin
    Tisdale, James E.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1719 - 1726
  • [28] TORSADES-DE-POINTES AFTER TREATMENT WITH TERFENADINE AND KETOCONAZOLE
    ZIMMERMANN, M
    DURUZ, H
    GUINAND, O
    BROCCARD, O
    LEVY, P
    LACATIS, D
    BLOCH, A
    EUROPEAN HEART JOURNAL, 1992, 13 (07) : 1002 - 1003
  • [29] ELECTROPHYSIOLOGIC MECHANISMS INVOLVED IN THE DEVELOPMENT OF TORSADES-DE-POINTES
    PRIORI, SG
    NAPOLITANO, C
    SCHWARTZ, PJ
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 (01) : 203 - 212
  • [30] Dofetilide-induced long QT and torsades de pointes
    Aktas, Mehmet K.
    Shah, Abrar H.
    Akiyama, Toshio
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2007, 12 (03) : 197 - 202